Morgan Stanley and COVID-19

Selected healthcare news for the capital firm - Morgan Stanley, and the healthcare topic - COVID-19. We have 1,091 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/3/2022 What's Ahead for Moderna Post 28% Drop | Nasdaq Nasdaq ... Morgan Stanley analyst Matthew Harrison stated that the Phase 1 data could put pressure on Moderna stock. He added that upside from the current product seems ‚Auunlikely.‚Au Harrison has a Hold rating on Moderna stock.What‚Aos Ahead? Moderna could continue to benefit from the development and sales of Spikevax (its COVID-19 vaccine). The company expects the APA‚Aos (advance purchase agreements) signed and commercial booster sales to ...
12/16/2021 Adagio Therapeutics Stock Doubles After Jefferies Report Yahoo News By Sam BougheddaInvesting.com ‚Ai Adagio Therapeutics Inc (NASDAQ:ADGI) stock has more than doubled Thursday following comments from Jefferies regarding the company's Covid antibody treatment.On Tuesday, Adagio's stock plummeted after it reported its antibody treatment for Covid-19 showed reduced effectiveness on the Omicron variant. It resulted in downgrades and price target reductions for the stock, with Morgan Stanley saying the news "will limit the drug's utility."However ...
12/16/2021 Apple Delays Office Return; Australia State Record: Virus Update Yahoo News Bloomberg) -- Apple Inc. is delaying its return to the office indefinitely as Covid-19 infections rise and Morgan Stanley has told some staff to work from home. Cases in the U.S. have jumped 60% since late October to an average of about 120,000 a day.Most Read from BloombergCan Indoor Farms Reach Skyscraper Height?Zero Taxes, Golf and Beach Houses Create a Crypto Island ParadiseChina Is Building the ...
12/14/2021 Adagio Therapeutics Tumbles On Omicron Data By Investing.com ... Investing.com ‚Ai Adagio Therapeutics Inc (NASDAQ: ADGI ) shares fell 78% Tuesday after the company reported that its antibody treatment for Covid-19 showed a reduced effectiveness to the Omicron variant.The company said external analyses ... play in preventing and treating Covid-19.The news surprised Morgan Stanley after previous in vitro studies showed ADG20 retained activity against prior variants, including Alpha, Beta, Delta and Gamma. As a result, the analysts ...
12/3/2021 Australia's CSL in exclusive talks for $7 billion buyout of Swiss Vifor Pharma ‚Äì report ... Morgan Stanley analysts said in a research note that CSL may be seeking diversification because blood plasma collections ‚Ai where it pays people to give blood, which it then converts to treatments ‚Ai remained depressed due to COVID-19 restrictions.‚AuDiversification could be wise, although it could lead to near-term de-rating until any potential synergies are evident to the market,‚Au the Morgan Stanley note said.Jefferies analysts ...
11/29/2021 33 Stocks Moving In Monday's Mid-Day Session Benzinga ... COVID-19 monoclonal antibody, ADG20, is likely to retain activity against Omicron, as observed in in vitro models with all other variants of concern identified previously. Morgan Stanley upgraded Adagio Therapeutics from Equal-Weight to Overweight and announced a $49 price target.- iSpecimen Inc. (NASDAQ: [ISPC] ) jumped 54.9% to $27.12 after jumping around 72% on Friday. The company recently announced a contract to support new advanced research on COVID-19 ...
10/14/2021 Premarket Movers Thursday - Bank of America, UnitedHealth, UPS - TheStreet TheStreet ... Covid-19 effects on its operating costs. Shares of Bed Bath & Beyond ( BBBY ) - Get Bed Bath & Beyond Inc. Report were lower after Morgan Stanley analysts downgraded the home-goods retailer to underweight from equal weight. Shares of Wayfair ( W ) - Get Wayfair, Inc. Class A Report slipped after analysts at Morgan Stanley and Jefferies downgraded the online furniture retailer's stock. Morgan Stanley downgraded Wayfair to underweight from equal weight ...
10/11/2021 Singapore to forge on with economic recovery, central bank on hold ... COVID-19 cases. ‚AuWe suspect what has likely held up relatively well are manufacturing and financial services, whilst some of the more contact-intensive segments such as retail/wholesale and food/lodging likely moderated more,‚Au Morgan Stanley economists said in a report last week. Singapore has fully vaccinated about 83% of its 5.45 million people against the virus but reimposed some coronavirus restrictions to buy time to prepare to ...
10/5/2021 Morgan Stanley: We need to get to the second half of 2022 to end the pandemic globally Duration: 04:17 16 mins ago Morgan Stanley analyst Matthew Harrison discusses the latest trends in COVID-19 cases and vaccinations, and the impact of the positive news about Merck's oral treatment, including other potential pills in the pipeline ...
10/5/2021 This biotech analyst thinks vaccination is the ‚Äúonly way‚Äù to end the pandemic AuWinter is coming‚Au ‚Ai could it fuel another surge in COVID-19 cases in the United States? Morgan Stanley‚Aos biotech analyst Matthew Harrison thinks so. But on a more positive note, he expects this to be the last ‚Ausubstantial increase‚Au in the U.S. Harrison‚Aos remarks on CNBC‚Aos ‚AuWorldwide Exchange‚Au Harrison expects the pandemic to end in the back half of 2022. On CNBC‚Aos ...
10/1/2021 Futures slip ahead of inflation, factory activity data ... infrastructure package remained in focus. Oil firms including Exxon Mobil and Chevron Corp slipped about 0.9% premarket, while big banks Morgan Stanley, JPMorgan Chase & Co, Citigroup, Bank of America and Goldman Sachs Group dropped 1 ... following a tumultuous month and quarter wrecked by concerns over COVID-19, inflation fears and budget wrangling in Washington. All eyes are now on consumer spending, inflation and factory activity data later in the day ...
9/30/2021 Ginkgo Bioworks Announces Participation in Upcoming Conferences PR Newswire ... MedTools Conference on Thursday, October 7, 2021 , at 11:15 a.m. Eastern Time . A fireside chat and 1x1 meetings at the Morgan Stanley Annual Spark Conference on Wednesday, October 13, 2021 , at 5:45 p.m. Eastern Time ... to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. , visit www.ginkgobioworks.com .Forward-Looking StatementsThis press release contains certain ...
9/24/2021 Elligo Health acquires clinical services firm ClinEdge for $135m Valneva starts recruitment of adolescents for Covid-19 vaccine trial in UK]Elligo Health acquires clinical services firm ClinEdge for $135mThe acquisition, which also includes GuideStar Research and BTC of New Bedford, was financed through investor funding.Elligo Health Research has acquired research practice management and clinical services firm ClinEdge in a $135m transaction.The deal was financed via new co-lead investors Morgan Stanley Expansion Capital and Ally ...
9/15/2021 Merck sees potential U.S. authorization for COVID-19 oral antiviral drug, Molnupiravir before year-end ... COVID-19 oral antiviral treatment, Molnupiravir, before year-end. "I would just say that our program is enrolling well, and we expect to be able to see clinical data in the back half of the year," Merck's Chief Executive Officer Robert Davis said at Morgan Stanley's Annual Global Healthcare Conference. Merck and partner Ridgeback Biotherapeutics are conducting a late-stage trial of molnupiravir in non-hospitalized COVID-19 patients to ...
9/13/2021 The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs Yahoo News ... among the biggest decliners of the week after the company said the Food and Drug Administration refused to authorize its COVID-19 treatment for emergency use. Mersana Therapeutics, Inc. (MRSN) and Apellis Pharmaceuticals, Inc. (APLS ... 2021 World Conference On Lung Cancer: Sept 8-14 (virtual event)Morgan Stanley 19th Annual Global Healthcare Conference: Sept. 9-15 (virtual event)BofA Global Healthcare Conference 2021: Sept. 15-16 (virtual event)European Society for Medical Oncology ...
9/13/2021 The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs Yahoo News ... among the biggest decliners of the week after the company said the Food and Drug Administration refused to authorize its COVID-19 treatment for emergency use. Mersana Therapeutics, Inc. (MRSN) and Apellis Pharmaceuticals, Inc. (APLS ... 2021 World Conference On Lung Cancer: Sept 8-14 (virtual event)Morgan Stanley 19th Annual Global Healthcare Conference: Sept. 9-15 (virtual event)BofA Global Healthcare Conference 2021: Sept. 15-16 (virtual event)European Society for Medical Oncology ...
9/13/2021 Capex Booms as Companies Prepare for a Post-Pandemic World ... side, blockages brought on by the Covid-19 pandemic are forcing businesses to invest in new production facilities; calls for a ... Ai especially in semiconductors, retail, software and transportation. Economists at Morgan Stanley forecast that global investment will reach 115% and 121% of pre-recession levels by the end of 2021 and end of 2022, a ...
9/13/2021 Capex Booms as Companies Prepare for a Post-Pandemic World ... plants and machinery in ways they haven‚Aot done for years. On the supply side, blockages brought on by the Covid-19 pandemic are forcing businesses to invest in new production facilities; calls for a ... Ai especially in semiconductors, retail, software and transportation. Economists at Morgan Stanley forecast that global investment will reach 115% and 121% of pre-recession levels by the end of 2021 and end of 2022, a ...
9/13/2021 Why Global Companies Are Spending Heavily On New Plants, Machinery ... new plants and machinery in ways they haven't done for years. On the supply side, blockages brought on by the Covid-19 pandemic are forcing businesses to invest in new production facilities; calls for a ... sectors -- especially in semiconductors, retail, software and transportation. Economists at Morgan Stanley forecast that global investment will reach 115% and 121% of pre-recession levels by the end of 2021 and end of 2022, a ...
9/13/2021 Merck sees potential U.S. authorization for COVID-19 antiviral before year-end Reuters) - Drugmaker Merck & Co Inc said on Monday it sees potential U.S. emergency use authorization for its experimental COVID-19 antiviral treatment, molnupiravir, before year-end."I would just say that our program is enrolling well, and we expect to be able to see clinical data in the back half of the year," Merck's Chief Executive Officer Robert Davis said at Morgan Stanley's Annual Global Healthcare Conference.Merck and partner ...
9/13/2021 Merck sees potential U.S. authorization for COVID-19 antiviral before year-end Enlarge(Reuters) ‚Ai Drugmaker Merck & Co Inc said on Monday it sees potential U.S. emergency use authorization for its experimental COVID-19 antiviral treatment, molnupiravir, before year-end.‚AuI would just say that our program is enrolling well, and we expect to be able to see clinical data in the back half of the year,‚Au Merck‚Aos Chief Executive Officer Robert Davis said at Morgan Stanley‚Aos Annual Global ...
9/12/2021 Global Capex Booms as Companies Prepare for Post-Pandemic Era ... plants and machinery in ways they haven‚Aot done for years. On the supply side, blockages brought on by the Covid-19 pandemic are forcing businesses to invest in new production facilities; calls for a ... sectors -- especially in semiconductors, retail, software and transportation. Economists at Morgan Stanley forecast that global investment will reach 115% and 121% of pre-recession levels by the end of 2021 and end of 2022, a ...
9/11/2021 Novavax expects to make available at least 2 billion COVID-19 vaccine doses in 2022 ... COVID-19 vaccine would be available in 2022. The company, which in June announced its vaccine was more than 90% effective in a late-stage U.S.-based clinical trial, said it was on track to file an application for emergency use of its vaccine to the U.S. Food and Drug Administration in the fourth quarter. Novavax, speaking at a Morgan Stanley healthcare conference, reiterated that it would have about 100 ...
9/11/2021 Novavax expects to make available at least 2 billion COVID-19 vaccine doses in 2022 ... COVID-19 vaccine would be available in 2022. The company, which in June announced its vaccine was more than 90% effective in a late-stage U.S.-based clinical trial, said it was on track to file an application for emergency use of its vaccine to the U.S. Food and Drug Administration in the fourth quarter. Novavax, speaking at a Morgan Stanley healthcare conference, reiterated that it would have about 100 ...
9/11/2021 Novavax expects to make available at least 2 billion COVID-19 vaccine doses in 2022 ... COVID-19 vaccine would be available in 2022. The company, which in June announced its vaccine was more than 90% effective in a late-stage U.S.-based clinical trial, said it was on track to file an application for emergency use of its vaccine to the U.S. Food and Drug Administration in the fourth quarter. Novavax, speaking at a Morgan Stanley healthcare conference, reiterated that it would have about 100 ...